{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:44:28Z","timestamp":1793137468840,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.mayocpiqo.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T20:54:16Z","timestamp":1663448056000},"page":"458-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-8228","authenticated-orcid":false,"given":"Meera","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9318-7091","authenticated-orcid":false,"given":"Maria A.V.","family":"Willrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.mayocpiqo.2022.03.005_bib2","first-page":"1379","article-title":"Eculizumab in atypical hemolytic-uremic syndrome","volume":"369","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mayocpiqo.2022.03.005_bib3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2022.03.005_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.mayocpiqo.2022.03.005_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jim.2018.06.010","article-title":"The impact of eculizumab on routine complement assays","volume":"460","author":"Willrich","year":"2018","journal-title":"J\u00a0Immunol Methods"},{"issue":"16","key":"10.1016\/j.mayocpiqo.2022.03.005_bib6","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/j.molimm.2007.06.150","article-title":"Complement analysis in the 21st century","volume":"44","author":"Mollnes","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.mayocpiqo.2022.03.005_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2016.06.001","article-title":"Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation","volume":"77","author":"Frazer-Abel","year":"2016","journal-title":"Adv Clin Chem"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.03.005_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s13361-016-1566-y","article-title":"Quantification of the IgG2\/4 kappa monoclonal therapeutic eculizumab from serum using isotype specific affinity purification and microflow LC-ESI-Q-TOF mass spectrometry","volume":"28","author":"Ladwig","year":"2017","journal-title":"J\u00a0Am Soc Mass Spectrom"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2022.03.005_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.mayocpiqo.2022.03.005_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.molimm.2017.05.013","article-title":"Complement in clinical medicine: clinical trials, case reports and therapy monitoring","volume":"89","author":"Ricklin","year":"2017","journal-title":"Mol Immunol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2022.03.005_bib11","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2022.03.005_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/cpt.686","article-title":"Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment","volume":"102","author":"Volokhina","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2022.03.005_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00467-017-3813-2","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update","volume":"33","author":"Ardissino","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2022.03.005_bib14","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jth.12615","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome","volume":"12","author":"Cugno","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.03.005_bib15","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/bcp.14627","article-title":"Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from a prospective multicentric study","volume":"87","author":"Passot","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.mayocpiqo.2022.03.005_bib16","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc1308826","article-title":"Eculizumab in atypical hemolytic-uremic syndrome","volume":"369","author":"Ring","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2022.03.005_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"}],"updated-by":[{"DOI":"10.1016\/j.mayocpiqo.2024.06.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000}}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454822000194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454822000194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T01:32:56Z","timestamp":1722907976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454822000194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2542454822000194"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2022.03.005","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.mayocpiqo.2024.06.004","asserted-by":"object"}]},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}